AC Immune (ACIU)
(Delayed Data from NSDQ)
$2.37 USD
-0.01 (-0.42%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $2.33 -0.04 (-1.69%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ACIU 2.37 -0.01(-0.42%)
Will ACIU be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ACIU based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ACIU
AbbVie (ABBV) Announces Appointment of New CEO Robert Michael
Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod
ACIU: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -35.7% in 4 Weeks, Here's Why AC Immune (ACIU) Looks Ripe for a Turnaround
AC Immune (ACIU) is a Great Momentum Stock: Should You Buy?
5 Small-Cap Stocks to Play the January Effect
Other News for ACIU
CALM, PLAY and VNDA are among after hour movers
CALM,PLAY and VNDA are among after hour movers
Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT), Fulcrum Therapeutics (FULC) and AC Immune SA (ACIU)
Buy Rating for AC Immune SA on Promising Alzheimer’s Vaccine Trial Design and Potential Accelerated Approval
ACIU Stock Earnings: AC Immune Beats EPS, Beats Revenue for Q4 2023